GRAPPA RECOGNIZES 6 CLINICAL DOMAINS TO ADDRESS IN THE TREATMENT OF PSORIATIC ARTHRITIS1
OTEZLA is an oral PDE4 inhibitor that has been included in the GRAPPA PsA treatment recommendations1,2
GRAPPA recommendations highlight the need to determine treatment
based in part on the domains involved in PsA and drug interactions that can
compromise the management of comorbidities1
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) is a global network of rheumatologists and dermatologists who have provided evidence-based guidance for the treatment and management of adult patients with psoriatic arthritis.1
CS, corticosteroid; CSA, cyclosporine A; IA, intraarticular; IL-12/23i, interleukin 12/23 inhibitor; PDE4i, phosphodiesterase 4 inhibitor (apremilast); phototx, phototherapy; SpA, spondyloarthritis; TNFi, tumornecrosis factor inhibitor ;vit, vitamin.
- Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis . Arthritis Rheumatol. 2016;68(5):1060-1071.
- OTEZLA Summary of Product Characteristics. Stockley Park, Uxbridge, UK:Celgene Europe, Ltd; 2017.